These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34493171)

  • 1. Prognostic significance of EZH2 and ARID1A expression in urothelial carcinoma: an immunohistochemical study.
    Sameh R; Mostafa N; Ramadan M; AbdelRaouf S; Abdelwahab K
    J Histotechnol; 2022 Mar; 45(1):21-28. PubMed ID: 34493171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
    Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
    PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors.
    Rehman H; Chandrashekar DS; Balabhadrapatruni C; Nepal S; Balasubramanya SAH; Shelton AK; Skinner KR; Ma AH; Rao T; Agarwal S; Eich ML; Robinson AD; Naik G; Manne U; Netto GJ; Miller CR; Pan CX; Sonpavde G; Varambally S; Ferguson JE
    JCI Insight; 2022 Aug; 7(16):. PubMed ID: 35852858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder.
    Hinz S; Kempkensteffen C; Christoph F; Hoffmann M; Krause H; Schrader M; Schostak M; Miller K; Weikert S
    J Cancer Res Clin Oncol; 2008 Mar; 134(3):331-6. PubMed ID: 17694325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer.
    Warrick JI; Raman JD; Kaag M; Bruggeman T; Cates J; Clark P; DeGraff DJ
    Urol Oncol; 2016 Jun; 34(6):258.e1-6. PubMed ID: 26976725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of EZH2 and H3K27me3 predicts tumor biology of urothelial carcinoma.
    Mohamedali R; Mitra S; Mandal S; Nayak P; Adhya AK; Purkait S
    Indian J Pathol Microbiol; 2023; 66(3):488-494. PubMed ID: 37530328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder.
    Wang H; Albadine R; Magheli A; Guzzo TJ; Ball MW; Hinz S; Schoenberg MP; Netto GJ; Gonzalgo ML
    Urol Oncol; 2012; 30(4):428-33. PubMed ID: 21396836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARID1A upregulation predicts better survival in patients with urothelial bladder carcinoma.
    Cao Q; Wang C; Ding Y; Xu D; Qian S; Shen H; Qi J
    J Int Med Res; 2020 Apr; 48(4):300060519895687. PubMed ID: 31891283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.
    Keller PJ; Adams EJ; Wu R; Côté A; Arora S; Cantone N; Meyer R; Mertz JA; Gehling V; Cui J; Stuckey JI; Khanna A; Zhao F; Chen Z; Yu Z; Cummings RT; Taimi M; Lakhani NJ; Rasco D; Gutierrez M; Duska L; Devitt M; Rippley R; Levell J; Truong J; Wang J; Sun K; Trojer P
    Cancer Res; 2024 Aug; 84(15):2501-2517. PubMed ID: 38833522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder.
    Faraj SF; Chaux A; Gonzalez-Roibon N; Munari E; Ellis C; Driscoll T; Schoenberg MP; Bivalacqua TJ; Shih IeM; Netto GJ
    Hum Pathol; 2014 Nov; 45(11):2233-9. PubMed ID: 25175170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of EZH2 indicates aggressive potential of urothelial carcinoma of the bladder in a Chinese population.
    Zhou X; Liu N; Zhang J; Ji H; Liu Y; Yang J; Chen Z
    Sci Rep; 2018 Dec; 8(1):17792. PubMed ID: 30542123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer.
    Dugas SG; Müller DC; Le Magnen C; Federer-Gsponer J; Seifert HH; Ruiz C; Savic Prince S; Vlajnic T; Zellweger T; Mertz KD; Bacon JVW; Wyatt AW; Rentsch CA; Bubendorf L
    Cancer Cytopathol; 2019 Sep; 127(9):578-585. PubMed ID: 31386310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder.
    Hinz S; Kempkensteffen C; Weikert S; Schostak M; Schrader M; Miller K; Christoph F
    Tumour Biol; 2007; 28(3):151-7. PubMed ID: 17541304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of ARID1A negative expression in gastric cancer.
    Ashizawa M; Saito M; Min AKT; Ujiie D; Saito K; Sato T; Kikuchi T; Okayama H; Fujita S; Endo H; Sakamoto W; Momma T; Ohki S; Goto A; Kono K
    Sci Rep; 2019 May; 9(1):6769. PubMed ID: 31043675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
    Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Different miRNAs and Their Relevant miRNA Targeted Genes Involved in Sister Chromatid Cohesion and Segregation (SCCS)/chromatin Remodeling Pathway on T1G3 Urothelial Carcinoma (UC) Response to BCG Immunotherapy.
    Awadalla A; Zahran MH; Abol-Enein H; Zekri AN; Elbaset MA; Ahmed AE; Hamam ET; Elsawy A; Khalifa MK; Shokeir AA
    Clin Genitourin Cancer; 2022 Jun; 20(3):e181-e189. PubMed ID: 34998699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors.
    Balbás-Martínez C; Rodríguez-Pinilla M; Casanova A; Domínguez O; Pisano DG; Gómez G; Lloreta J; Lorente JA; Malats N; Real FX
    PLoS One; 2013; 8(5):e62483. PubMed ID: 23650517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.
    Arisan S; Buyuktuncer ED; Palavan-Unsal N; Caşkurlu T; Cakir OO; Ergenekon E
    Urol Int; 2005; 75(3):252-7. PubMed ID: 16215315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas.
    Weikert S; Christoph F; Köllermann J; Müller M; Schrader M; Miller K; Krause H
    Int J Mol Med; 2005 Aug; 16(2):349-53. PubMed ID: 16012774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.